Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00054041
Completed
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia
Gender:
FEMALE
Ages:
17 years and above
Trial Updated:
01/23/2013
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Register for Updates
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
NCT00003023
Completed
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Sarcoma
Register for Updates
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
01/17/2013
Locations: Not set, Fayetteville, Arkansas +36 locations
Conditions: Vaccines, Pneumococcal
Register for Updates
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052
Completed
The purpose of this study is to evaluate the safety of a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, compared to the safety of a similar, licensed meningococcal A/C/Y/W-135-DT conjugate vaccine. The investigators will also evaluate the production of antibodies to of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine, as a measure of vaccine effectiveness.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/11/2013
Locations: Kings Cardiology Group, Hanford, California
Conditions: Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
NCT00100971
Terminated
RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2013
Locations: Cancer Research Center at Boston Medical Center, Boston, Massachusetts
Conditions: Leukemia
Register for Updates
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
NCT00919178
Completed
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties. The World Health Organization (WHO) estimates that these viruses are responsible for more than 50 million cases of dengue fever (DF) and approximately 0.5 million cases of the more severe disease, dengue hemorrhagic fever/ shock syndrome (DHF/DSS) annually. Because dengue viruses are endemic in most tropical and subtropical regions, keeping more than 2 billion p... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland +1 locations
Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Register for Updates
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
NCT01072786
Completed
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses of five formulations of a tetravalent dengue virus vaccine in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Center for Immunization Research, Johns Hopkins School of Public Health, Washington, District of Columbia +3 locations
Conditions: Dengue
Register for Updates
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
NCT01084291
Completed
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. There are four types of dengue virus, and infection with one does not offer protection against the others. This study will test whether a vaccine developed to prevent infection with dengue virus type 1 (DEN1) causes a response in people's immune system and is safe.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Fletcher Allen Health Care (FAHC) General Clinical Research Center (GCRC), Burlington, Vermont +1 locations
Conditions: Dengue Virus
Register for Updates
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429
Completed
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/13/2012
Locations: Not set, Hoover, Alabama +14 locations
Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Register for Updates
Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
NCT01215149
Completed
The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and homologous prime-boost regimens at different time intervals.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/13/2012
Locations: Brigham and Women's Hospital, Boston, Massachusetts +5 locations
Conditions: HIV Infections
Register for Updates
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer
NCT00437502
Completed
This study will evaluate the safety of administering a peptide vaccine consisting of twelve different tumor-rejection antigens known to be present on ovarian tumor cells. The vaccine is designed to elicit immune responses against twelve different pathways that are essential to tumor growth, survival and metastasis.HLA-A2+ is a required criteria for subject eligibility.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/15/2012
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
Register for Updates
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
NCT01163747
Completed
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2012
Locations: Not set, Anniston, Alabama +46 locations
Conditions: Rheumatoid Arthritis
Register for Updates